1020 |
CYCLIN DEPENDENT KINASE 5 |
CDK5 |
LIS7 |
PSSALRE |
123831 |
1774 |
ENSG00000164885 |
OTTHUMG00000158414 |
Q00535 |
CDKN5 |
Cyclin-dependent-like kinase 5 |
TPKII catalytic subunit |
Tau protein kinase II catalytic subunit |
Serine/threonine-protein kinase PSSALRE |
Cell division protein kinase 5 |
cyclin-dependent kinase 5 |
CDK5_HUMAN |
CELL DIVISION PROTEIN KINASE 5 (EC 2.7.1.37) (TAU PROTEIN KINASE II CATALYTIC SUBUNIT) (TPKII CATALYTIC SUBUNIT) (SERINE/THREONINE-PROTEIN KINASE PSSALRE). [SOURCE:UNIPROT/SWISSPROT;ACC:Q00535] |
CDK 1,2,5,9 |
CDK 1,2,4,5,6,7,9 (pan-CDK) |
T20973 |
Interpro Short Name | Ser/Thr_dual-sp_kinase_dom |
Interpro Name | Serine/threonine- / dual-specificity protein kinase, catalytic domain |
Uniprot Evidence | 1: Evidence at protein level |
Interpro Type | Domain |
Interpro Acc | IPR002290 |
Human Readable Name | DRUGGABLE GENOME |
Human Readable Name | KINASE |
Uniprot Status | Swiss-Prot |
Target Class | Enzymes |
Target Subclass | EC:2.7.11.22 |
CancerCommons Reported Gene Name | CDK1,2,5,9 |
Gene Biotype | PROTEIN_CODING |
TUMOR SUPPRESSOR |
KINASE |
SERINE THREONINE KINASE |
DRUGGABLE GENOME |
ENZYME |
inhibitor (inhibitory) |
Mechanism of Interaction | Cyclin-dependent kinase 5 inhibitor |
Direct Interaction | yes |
Reported Cancer Type | Melanoma |
inhibitor (inhibitory) |
Trial Name | flavopiridol, alvocidib, HMR-1275 |
Novel drug target | Novel Target |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Cyclin-dependent kinase 5 inhibitor |
inhibitor (inhibitory) |
Mechanism of Interaction | Cyclin-dependent kinase 5 inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Cyclin-dependent kinase inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Cyclin-dependent kinase inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Cyclin-dependent kinase inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Cyclin-dependent kinase inhibitor |
CDK5 | Ensembl Gene Name |
Gene Biotype | PROTEIN_CODING |
CDK5_HUMAN | Uniprot Id |
ENSG00000164885 | Ensembl Gene Id |
1020 | Entrez Gene Id |
Interpro Short Name | Ser/Thr_dual-sp_kinase_dom |
Interpro Name | Serine/threonine- / dual-specificity protein kinase, catalytic domain |
Uniprot Evidence | 1: Evidence at protein level |
KINASE, DRUGGABLE GENOME |
1020 | Entrez Gene ID |
CancerCommons Reported Gene Name | CDK1,2,5,9 |
CDK5 | Gene Symbol |
Target Class | Enzymes |
Target Subclass | EC:2.7.11.22 |
CELL DIVISION PROTEIN KINASE 5 (EC 2.7.1.37) (TAU PROTEIN KINASE II CATALYTIC SUBUNIT) (TPKII CATALYTIC SUBUNIT) (SERINE/THREONINE-PROTEIN KINASE PSSALRE). [SOURCE:UNIPROT/SWISSPROT;ACC:Q00535] | Description |
ENSG00000164885 | Ensembl Gene Id |
CDK5 | Display Id |
Human Readable Name | DRUGGABLE GENOME |
DRUGGABLE GENOME |
ENSG00000164885 | Gene Symbol |
CDK5 | Ensembl Id |
DRUGGABLE GENOME |
CDKN5 | GENE_SYMBOL |
CDK5 | GENE_SYMBOL |
Cyclin-dependent-like kinase 5 | UNIPROT |
1020 | Entrez Gene Id |
CDK5 | MyCancerGenome Gene Symbol |
CDK 1,2,4,5,6,7,9 (pan-CDK) | MyCancerGenome Reported Gene Name |
ENSG00000164885 | Ensembl Gene ID |
PSSALRE | Human Protein Atlas Gene Synonym |
Cyclin dependent kinase 5 | Human Protein Atlas Gene Description |
ENZYME |
CDKN5 | GO Gene Synonym |
TUMOR SUPPRESSOR, KINASE, SERINE THREONINE KINASE |
1020 | Gene ID |
PSSALRE | dGene Synonym |
KINASE, SERINE THREONINE KINASE |
CDK5 | TTD Gene Abbreviation |
T20973 | TTD Target ID |
Cyclin-dependent-like kinase 5 | Gene Name |
Q00535 | UniProt ID |
KINASE |